PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Aptar Pharma’s Preservative-Free Multidose Dispenser Approved for Anti-Allergy Treatment by French Regulatory Agency ANSM

Aptar Pharma’s innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the approved delivery device for Bausch+Lomb’s Levofree Multidose in France. This marks the first approval by the French National Agency for Medicines and Health Products Safety (ANSM) for Aptar Pharma’s Ophthalmic Squeeze Dispenser.
Levofree is a prescription product for the treatment of allergic conjunctivitis. ANSM approved the multidose dispenser and drug combination in May 2018. This approval further expands the regulatory acceptance of Aptar Pharma’s Ophthalmic Squeeze Dispenser as an approved delivery system for preservative-free Eye Care formulations.

 
Addressing the needs of patients and industry
When developing novel Eye Care products, pharmaceutical companies need to deliver improved patient safety, accurate dosing and product integrity. Aptar Pharma’s Ophthalmic Squeeze Dispenser meets these key industry and patient needs.
 
Meeting regulatory requirements worldwide
Aptar Pharma has been working closely with Bausch+Lomb, one of the world’s leading Eye Care companies, to achieve this first ANSM approval of an Eye Care product in its multidose device
The ANSM approval culminates a long and robust process. Prior to approval, Bausch and Lomb provided comprehensive, detailed microbiological study results which showed that microorganisms can neither survive nor form colonies in or on the container. In addition, user studies were performed that confirmed the user-friendliness of the multidose device within the patient target group.
The Ophthalmic Squeeze Dispenser is also the first and only FDA-reviewed delivery system for multidose, preservative-free Eye Care products.
 
Global acceptance
With more than 150 commercial references worldwide, Aptar Pharma’s Ophthalmic Squeeze Dispenser continues to meet the evolving needs of consumers, patients and the industry. The ergonomic intuitiveness of the squeezable container with a low actuation force contributes to the high levels of acceptance.
 
Aptar Pharma’s proven expertise in Eye Care
Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions.
“Our Ophthalmic Dispenser technology has been a great success for our customers,” explained Matthias Birkhoff, Vice President Business Development, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection, allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the French ANSM with confidence.”
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026